Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trialNancy Y. Lee, Ezra E.W. Cohen, Robert L. Ferris et al.|The Lancet Oncology|2021Cited by 618
Randomized Phase II Trial of Nivolumab With Stereotactic Body Radiotherapy Versus Nivolumab Alone in Metastatic Head and Neck Squamous Cell CarcinomaSean M. McBride, Nancy Y. Lee, Loren S. Michel et al.|Journal of Clinical Oncology|2020Cited by 393
Preexisting tumor-resident T cells with cytotoxic potential associate with response to neoadjuvant anti–PD-1 in head and neck cancerGiacomo Oliveira, Ravindra Uppaluri, Ann Marie Egloff et al.|Science Immunology|2023Cited by 118
Enhanced pathologic tumor response with two cycles of neoadjuvant pembrolizumab in surgically resectable, locally advanced HPV-negative head and neck squamous cell carcinoma (HNSCC).Ravindra Uppaluri, Douglas R. Adkins, Rebecca D. Chernock et al.|Journal of Clinical Oncology|2021Cited by 40